Patients with newly diagnosed primary estrogen-receptor (ER) positive breast cancer, with at
least one breast lesion that is 1.0 cm in diameter or greater, may be eligible for this
study. Patients may participate in this study if they are at least 18 years of age. Up to 20
evaluable subjects will participate in a single imaging cohort. Study subjects will undergo
imaging of the breast with a novel device combining dedicated Breast Positron Emission
Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of
[18F]-Fluoroestradiol (FES). This is an observational study; FES-BPET/DBT will not be used to
direct treatment decisions. While patients and referring physicians will not be blinded to
the FES-BPET/DBT results, treatment decisions are made by the treating physicians based upon
standard clinical imaging.
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania